To say the market has started the year off on the wrong foot is an understatement. This is especially true in the high beta NASDAQ growth names. The Nazzy is now off to the worst start to a year since 2008. Nervousness about the markets is evident. Both the VIX and VXN -or VIX of the NASDAQ- are near the…
Earlier this year, the biotech company featured in today’s article was a penny stock. But after uplisting to the Nasdaq, the author of today’s article notes that “it has been making big moves in the market and moving some of Wall Street’s top analysts to set initial targets over $20 right now.” For more on how this company’s approach to…
A clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics and a clinical- stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer’s disease and Parkinson’s disease are among seven new biotech stocks to watch highlighted in today’s article, which also highlights new stocks to watch in the tech, defense, and real estate sectors. For these…
When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run.…